Tai康 Biotech Announces Expanded NHI Coverage for Biosimilar Drug 'Yikangping Lyophilized Injection 420mg (EIRGASUN vial 420mg)' Starting July 1
Key facts
- Tai康 Biotech Announces Expanded NHI Coverage for Biosimilar Drug 'Yikangping Lyophilized Injection 420mg (EIRGASUN vial 420mg)' Starting July 1
- Tai康 Biotech announced the expansion of national health insurance coverage for its biosimilar drug EIRGASUN 420mg for HER2-positive early breast cancer, effective July 1, 2026, enhancing patient access and expected to positively impact company operations.
- Source: PR Times
- Date: June 16, 2026
Direct answer
Tai康 Biotech announced the expansion of national health insurance coverage for its biosimilar drug EIRGASUN 420mg for HER2-positive early breast cancer, effective July 1, 2026, enhancing patient access and expected to positively impact company operations.
- Citation
- Tai康 Biotech Announces Expanded NHI Coverage for Biosimilar Drug 'Yikangping Lyophilized Injection 420mg (EIRGASUN vial 420mg)' Starting July 1 (June 16, 2026), PR Times
- Source
- PR Times
- Date
- June 16, 2026
Tai康 Biotech announced the expansion of national health insurance coverage for its biosimilar drug EIRGASUN 420mg for HER2-positive early breast cancer, effective July 1, 2026, enhancing patient access and expected to positively impact company operations.
📋 Article Processing Timeline
- 📰 Published: June 16, 2026 at 09:00
- 🔍 Collected: June 17, 2026 at 17:00 (32h 0m after Published)
- 🤖 AI Analyzed: June 18, 2026 at 16:38 (23h 38m after Collected)
1. Date of Event: June 16, 2026
2. Company Name: Tai康 Biotech Co., Ltd.
3. Relationship to Company: Company itself
4. Cross-shareholding Ratio: Not applicable
5. Reason for Announcement:
(1) The Central Bureau of National Health Insurance, Ministry of Health and Welfare, announced today that starting July 1, 2026, the national health insurance coverage for EIRGASUN 420mg will be further expanded for the treatment of HER2-positive early breast cancer (EBC), aligning more closely with international treatment guidelines. The drug was already included in the National Health Insurance reimbursement list starting June 1, 2026.
(2) This expansion of insurance coverage is expected to improve clinical accessibility and have a positive impact on the company's operations.
(3) According to the Medical Technology Assessment Report by the Foundation of Medical Affairs Evaluation Center, approximately 1,566 to 1,755 early breast cancer patients per year are expected to benefit from this drug over the next five years.
6. Response Measures: Release of material information.
7. Other Matters to be Disclosed: None
Keywords: Material Information
2. Company Name: Tai康 Biotech Co., Ltd.
3. Relationship to Company: Company itself
4. Cross-shareholding Ratio: Not applicable
5. Reason for Announcement:
(1) The Central Bureau of National Health Insurance, Ministry of Health and Welfare, announced today that starting July 1, 2026, the national health insurance coverage for EIRGASUN 420mg will be further expanded for the treatment of HER2-positive early breast cancer (EBC), aligning more closely with international treatment guidelines. The drug was already included in the National Health Insurance reimbursement list starting June 1, 2026.
(2) This expansion of insurance coverage is expected to improve clinical accessibility and have a positive impact on the company's operations.
(3) According to the Medical Technology Assessment Report by the Foundation of Medical Affairs Evaluation Center, approximately 1,566 to 1,755 early breast cancer patients per year are expected to benefit from this drug over the next five years.
6. Response Measures: Release of material information.
7. Other Matters to be Disclosed: None
Keywords: Material Information
FAQ
What does the expanded insurance coverage mean?
More HER2-positive early breast cancer patients can access affordable treatment, increasing clinical adoption.
When will the drug be available under expanded coverage?
The expanded reimbursement takes effect on July 1, 2026, enabling broader prescription access.
How many patients will benefit?
Approximately 1,566 to 1,755 early breast cancer patients per year are expected to benefit.